Staphylococcus aureus toxins and diabetic foot ulcers: Role in pathogenesis and interest in diagnosis

Toxins

Volumn 8, Issue 7, 2016, Pages 1-20

  Dunyach Remy, Catherine ^a,b   Essebe, Christelle Ngba ^a   Sotto, Albert ^a,b   Lavigne, Jean Philippe ^a,b  

^a UNIV MONTPELLIER   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Diabetic foot infection; Staphylococcus aureus; Toxins

Indexed keywords

ALPHA TOXIN; BACTERIAL TOXIN; ENTEROTOXIN; EXFOLIATIN; HEMOLYSIN; MATRIX METALLOPROTEINASE; PANTON VALENTINE LEUKOCIDIN; TOXIC SHOCK SYNDROME TOXIN 1; VIRULENCE FACTOR;

CELL DIFFERENTIATION; CHRONIC WOUND; DIABETIC FOOT; GENE CLUSTER; HOSPITAL INFECTION; HYPERGLYCEMIA; LIMB PERFUSION; OSTEOMYELITIS; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; REVIEW; STAPHYLOCOCCUS AUREUS; TOXIC SHOCK SYNDROME; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PROGNOSIS; RISK FACTOR; STAPHYLOCOCCUS INFECTION; VIRULENCE; WOUND INFECTION;

BACTERIAL TOXINS; DIABETIC FOOT; HOST-PATHOGEN INTERACTIONS; HUMANS; OSTEOMYELITIS; PROGNOSIS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE; VIRULENCE FACTORS; WOUND INFECTION;

EID: 84978971720     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8070209     Document Type: Review

References (177)

1. Singh, N.; Armstrong, D.G.; Lipsky, B.A. Preventing foot ulcers in patients with diabetes. JAMA 2005, 293, 217-228. [CrossRef] [PubMed]
2. Prompers, L.; Huijberts, M.; Schaper, N.; Apelqvist, J.; Bakker, K.; Edmonds, M.; Holstein, P.; Jude, E.; Jirkovska, A.; Mauricio, D.; et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008, 51, 1826-1834. [CrossRef] [PubMed]
3. Lipsky, B.A.; Berendt, A.R.; Deery, H.G.; Embil, J.M.; Joseph,W.S.; Karchmer, A.W.; LeFrock, J.L.; Lew, D.P.; Mader, J.T.; Norden, C.; et al. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 2004, 39, 885-910. [CrossRef] [PubMed]
4. Lavery, L.A.; Armstrong, D.G.; Wunderlich, R.P.; Tredwell, J.; Boulton, A.J. Diabetic foot syndrome: Evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003, 26, 1435-1438. [CrossRef] [PubMed]
5. Jeffcoate,W.J.; Lipsky, B.A.; Berendt, A.R.; Cavanagh, P.R.; Bus, S.A.; Peters, E.J.; van Houtum,W.H.; Valk, G.; Bakker, K. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet. Med. 2008, 25, 1380-1389. [CrossRef] [PubMed]
6. Lavery, L.A.; Armstrong, D.G.;Wunderlich, R.P.; Mohler, M.J.;Wendel, C.S.; Lipsky, B.A. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006, 29, 1288-1293. [CrossRef] [PubMed]
7. Richard, J.L.; Lavigne, J.P.; Sotto, A. Diabetes and foot infection: More than double trouble. Diabetes Metab. Res. Rev. 2012, 28, 46-53. [CrossRef] [PubMed]
8. Spichler, A.; Hurwitz, B.L.; Armstrong, D.G.; Lipsky, B.A. Microbiology of diabetic foot infections: From Louis Pasteur to "crime scene investigation". BMC Med. 2015, 13, 2. [CrossRef] [PubMed]
9. Lavigne, J.P.; Sotto, A.; Dunyach-Remy, C.; Lipsky, B.A. New molecular techniques to study the skin microbiota of diabetic foot ulcers. Adv. Wound Care 2015, 4, 38-49. [CrossRef] [PubMed]
10. Edmonds, M. Infection in the neuroischemic foot. Int. J. Low. Extrem. Wounds 2005, 4, 145-153. [CrossRef] [PubMed]
11. Williams, D.T.; Hilton, J.R.; Harding, K.G. Diagnosing foot infection in diabetes. Clin. Infect. Dis. 2004, 39, S83-S86. [CrossRef] [PubMed]
12. Armstrong, D.G.; Lavery, L.A.; Sariaya, M.; Ashry, H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J. Foot Ankle Surg. 1996, 35, 280-283. [CrossRef]
13. Eneroth, M.; Larsson, J.; Apelqvist, J. Deep foot infections in patients with diabetes and foot ulcer: An entity with different characteristics, treatments, and prognosis. J. Diabetes Complicat. 1999, 13, 254-263. [CrossRef]
14. Eneroth, M.; Apelqvist, J.; Stenström, A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int. 1997, 18, 716-722. [CrossRef] [PubMed]
15. Lipsky, B.A. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab. Res. Rev. 2004, 20, S68-S77. [CrossRef] [PubMed]
16. Richard, J.L.; Sotto, A.; Lavigne, J.P. New insights in diabetic foot infection. World J. Diabetes 2011, 15, 24-32. [CrossRef] [PubMed]
17. Messad, N.; Landraud, L.; Canivet, B.; Lina, G.; Richard, J.L.; Sotto, A.; Lavigne, J.P. Distribution of edin in Staphylococcus aureus isolated from diabetic foot ulcers. Clin. Microbiol. Infect. 2013, 19, 875-880. [CrossRef] [PubMed]
18. Gardner, S.E.; Hillis, S.L.; Heilmann, K.; Segre, J.A.; Grice, E.A. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. Diabetes 2013, 62, 923-930. [CrossRef] [PubMed]
19. Hatipoglu, M.; Mutluoglu, M.; Turhan, V.; Uzun, G.; Lipsky, B.A.; Turk-DAY Study Group; Sevim, E.; Demiraslan, H.; Eryilmaz, E.; Ozuguz, C.; et al. Causative pathogens and antibiotic resistance in diabetic foot infections: A prospective multi-center study. J. Diabetes Complicat. 2016, 30, 910-916. [CrossRef] [PubMed]
20. Commons, R.J.; Robinson, C.H.; Gawler, D.; Davis, J.S.; Price, R.N. High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE study). Diabetes Res. Clin. Pract. 2015, 110, 147-157. [CrossRef] [PubMed]
21. Lesens, O.; Desbiez, F.; Theïs, C.; Ferry, T.; Bensalem, M.; Laurichesse, H.; Tauveron, I.; Beytout, J.; Aragón-Sánchez, J.; Working Group on Diabetic Osteomyelitis. Staphylococcus aureus-related diabetic osteomyelitis: Medical or surgical management? A French and Spanish retrospective cohort. Int. J. Low. Extrem. Wounds 2015, 14, 284-290. [CrossRef] [PubMed]
22. Serra, R.; Grande, R.; Butrico, L.; Rossi, A.; Settimio, U.F.; Caroleo, B.; Amato, B.; Gallelli, L.; de Franciscis, S. Chronic wound infections: The role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev. Anti-Infect. Ther. 2015, 13, 605-613. [CrossRef] [PubMed]
23. Wertheim, H.F.; Melles, D.C.; Vos, M.C.; van Leeuwen,W.; van Belkum, A.; Verbrugh, H.A.; Nouwen, J.L. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 2005, 5, 751-762. [CrossRef]
24. Tong, S.Y.; David, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G., Jr. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015, 28, 603-661. [CrossRef] [PubMed]
25. Lipsky, B.A.; Aragon-Sanchez, J.; Embil, J.; Kono, S.; Lavery, L.; Senneville, E.; Urbancic-Rovan, V.; Van Asten, S.; Peters, E.J.G.; International Working Group on the Diabetic Foot (IWGDF). IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab. Res. Rev. 2016, 32, 45-74. [CrossRef] [PubMed]
26. Shaper, N.C. Diabetic foot ulcer classification system for research purposes: A progress report on criteria for including patients in research studies. Diabetes Metab. Res. Rev. 2004, 20, S90-S95. [CrossRef] [PubMed]
27. Lipsky, B.A.; Berendt, A.R.; Cornia, P.B.; Pile, J.C.; Peters, E.J.; Armstrong, D.G.; Deery, H.G.; Embil, J.M.; Joseph,W.S.; Karchmer, A.W.; et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. J. Am. Podiatr. Med. Assoc. 2013, 103, 2-7. [CrossRef] [PubMed]
28. Lipsky, B.A. Osteomyelitis of the foot in diabetic patients. Clin. Infect. Dis. 1997, 25, 1318-1326. [CrossRef] [PubMed]
29. Markanday, A. Diagnosing diabetic foot osteomyelitis: Narrative review and a suggested 2-step score-based diagnostic pathway for clinicians. Open Forum Infect. Dis. 2014, 1, ofu060. [CrossRef] [PubMed]
30. Newman, L.G.; Waller, J.; Palestro, C.J.; Schwartz, M.; Klein, M.J.; Hermann, G.; Harrington, E.; Harrington, M.; Roman, S.H.; Stagnaro-Green, A. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991, 266, 1246-1251. [CrossRef] [PubMed]
31. Lazaro, J.L.; Izzo, V.; Meaume, S.; Davies, A.H.; Lobmann, R.; Uccioli, L. Elevated levels of matrix metalloproteinases and chronic wound healing: An updated review of clinical evidence. J. Wound Care 2016, 25, 277-287. [CrossRef] [PubMed]
32. McCarty, S.M.; Cochrane, C.A.; Clegg, P.D.; Percival, S.L. The role of endogenous and exogenous enzymes in chronic wounds: A focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. Wound Repair Regen. 2012, 20, 125-136. [CrossRef] [PubMed]
33. Ren, Y.; Gu, G.; Yao, M.; Driver, V.R. Role of matrix metalloproteinases in chronic wound healing: Diagnostic and therapeutic implications. Chin. Med. J. 2014, 127, 1572-1581. [PubMed]
34. Chang, M. Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective. Pharmacol. Res. 2016, 107, 243-248. [CrossRef] [PubMed]
35. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003, 92, 827-839. [CrossRef] [PubMed]
36. Li, Z.; Guo, S.; Yao, F.; Zhang, Y.; Li, T. Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers. J. Diabetes Complicat. 2013, 27, 380-382. [CrossRef] [PubMed]
37. Yager, D.R.; Zhang, L.Y.; Liang, H.X.; Diegelmann, R.F.; Cohen, I.K. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J. Investig. Dermatol. 1996, 107, 743-748. [CrossRef] [PubMed]
38. Saito, S.; Trovato, M.J.; You, R.; Lal, B.K.; Fasehun, F.; Padberg, F.T., Jr.; Hobson, R.W., 2nd; Durán, W.N.; Pappas, P.J. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J. Vasc. Surg. 2001, 34, 930-938. [CrossRef] [PubMed]
39. Lobmann, R.; Ambrosch, A.; Schultz, G.; Waldmann, K.; Schiweck, S.; Lehnert, H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002, 45, 1011-1016. [CrossRef] [PubMed]
40. Grinnell, F.; Zhu, M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J. Investig. Dermatol. 1996, 106, 335-341. [CrossRef] [PubMed]
41. Tentolouris, N.; Petrikkos, G.; Vallianou, N.; Zachos, C.; Daikos, G.L.; Tsapogas, P.; Markou, G.; Katsilambros, N. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect. 2006, 12, 186-189. [CrossRef] [PubMed]
42. Game, F.; Jeffcoate, W. MRSA and osteomyelitis of the foot in diabetes. Diabet. Med. 2004, 21, 16-19. [CrossRef] [PubMed]
43. Dang, C.N.; Prasad, Y.D.; Boulton, A.J.; Jude, E.B. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: A worsening problem. Diabet. Med. 2003, 20, 159-161. [CrossRef] [PubMed]
44. Barshes, N.R.; Rodriguez-Barradas, M.C.; Bechara, C.F.; Pisimisis, G.; Young, E.J.; Kougias, P. Microbial isolates and their antimicrobial susceptibilities in inframalleolar foot infections. Surg. Infect. 2014, 15, 585-591. [CrossRef] [PubMed]
45. Citron, D.M.; Goldstein, E.J.; Merriam, C.V.; Lipsky, B.A.; Abramson, M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 2007, 45, 2819-2828. [CrossRef] [PubMed]
46. Lavery, L.A.; Harkless, L.B.; Felder-Johnson, K.; Mundine, S. Bacterial pathogens in infected puncture wounds in adults with diabetes. J. Foot Ankle Surg. 1994, 33, 91-97. [PubMed]
47. Lavery, L.A.; Sariaya, M.; Ashry, H.; Harkless, L.B. Microbiology of osteomyelitis in diabetic foot infections. J. Foot Ankle Surg. 1995, 34, 61-64. [CrossRef]
48. Djahmi, N.; Messad, N.; Nedjai, S.; Moussaoui, A.; Mazouz, D.; Richard, J.L.; Sotto, A.; Lavigne, J.P. Molecular epidemiology of Staphylococcus aureus strains isolated from inpatients with infected diabetic foot ulcers in an Algerian University Hospital. Clin. Microb. Infect. 2013, 19, E398-E404. [CrossRef] [PubMed]
49. Richard, J.L.; Lavigne, J.P.; Got, I.; Hartemann, A.; Malgrange, D.; Tsirtsikolou, D.; Baleydier, A.; Senneville, E. Management of patients hospitalized for diabetic foot infection: Results of the French OPIDIA study. Diabetes Metab. 2011, 37, 208-215. [CrossRef] [PubMed]
50. Al Benwan, K.; Al Mulla, A.; Rotimi, V.O. A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwai. J. Infect. Public Health 2012, 5, 1-8. [CrossRef] [PubMed]
51. Akhi, M.T.; Ghotaslou, R.; Asgharzadeh, M.; Varshochi, M.; Pirzadeh, T.; Memar, M.Y.; Zahedi Bialvaei, A.; Seifi Yarijan Sofla, H.; Alizadeh, N. Bacterial etiology and antibiotic susceptibility pattern of diabetic foot infections in Tabriz, Iran. GMS Hyg. Infect. Control 2015, 10, Doc02. [CrossRef] [PubMed]
52. Anvarinejad, M.; Pouladfar, G.; Japoni, A.; Bolandparvaz, S.; Satiary, Z.; Abbasi, P.; Mardaneh, J. Isolation and antibiotic susceptibility of the microorganisms isolated from diabetic foot infections in Nemazee Hospital, Southern Iran. J. Pathog. 2015, 2015. [CrossRef] [PubMed]
53. Alavi, S.M.; Khosravi, A.D.; Sarami, A.; Dashtebozorg, A.; Montazeri, E.A. Bacteriologic study of diabetic foot ulcer. Pak. J. Med. Sci. 2007, 235, 681-684. [CrossRef]
54. Raja, N.S. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: A retrospective study of 194 cases. J. Microbiol. Immunol. Infect. 2007, 40, 39-44. [PubMed]
55. Yoga, R.; Khairul, A.; Sunita, K.; Suresh, C. Bacteriology of diabetic foot lesions. Med. J. Malays. 2006, 61, 14-16.
56. Martinez-Gomez Dde, A.; Ramirez-Almagro, C.; Campillo-Soto, A.; Morales-Cuenca, G.; Pagan-Ortiz, J.; Aguayo-Albasini, J.L. Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms. Enferm. Infecc. Microbiol. Clin. 2009, 27, 317-321. [PubMed]
57. Perim, M.C.; Bordes Jda, C.; Celeste, S.R.; Orsolin Ede, F.; Mendes, R.R.; Mendes, G.O.; Ferreira, R.L.; Carreiro, S.C.; Pranchevicius, M.C. Aerobic bacterial profile and antibiotic resistance in patients with diabetic foot infections. Rev. Soc. Bras. Med. Trop. 2015, 48, 546-554. [CrossRef] [PubMed]
58. Shanmugam, P.; Jeya, M.; Linda Susan, S. The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. J. Clin. Diagn. Res. 2013, 7, 441-445. [CrossRef] [PubMed]
59. Sugandhi, P.; Prasanth, D.A. Microbiological profile of bacterial pathogens from diabetic foot infections in tertiary care hospitals, Salem. Diabetes Metab. Syndr. 2014, 8, 129-132. [CrossRef] [PubMed]
60. Mathangi, T.; Prabhakaran, P.; Rayappan, F.; Tilton, F. Isolation, molecular characterization and antibiogram of bacteria isolated from DFU. Int. J. Curr. Res. Acad. Rev. 2013, 1, 17-25.
61. Sekhar, S.M.; Vyas, N.; Unnikrishnan, M.K.; Rodrigues, G.S.; Mukhopadhyay, C. Antimicrobial susceptibility pattern in diabetic foot ulcer: A pilot study. Ann. Med. Health Sci. Res. 2014, 4, 742-745. [CrossRef] [PubMed]
62. Wang, S.H.; Sun, Z.L.; Guo, Y.J.; Yang, B.Q.; Yuan, Y.;Wei, Q.; Ye, K.P. Meticillin-resistant Staphylococcus aureus isolated from foot ulcers in diabetic patients in a Chinese care hospital: Risk factors for infection and prevalence. J. Med. Microbiol. 2010, 59, 1219-1224. [CrossRef] [PubMed]
63. Ding, Q.; Li, D.Q.; Wang, P.H.; Chu, Y.J.; Meng, S.Y.; Sun, Q. Risk factors for infections of methicillin-resistant Staphylococci in diabetic foot patients. Zhonhua Yi Xue Za Zhi 2012, 92, 228-231.
64. Sharma, V.K.; Khadka, P.B.; Joshi, A.; Sharma, R. Common pathogens isolated in diabetic foot infection in Bir Hospital. Kathmandu Univ. Med. J. 2006, 4, 295-301.
65. Islam, S.; Cawich, S.O.; Budhooram, S.; Harnarayan, P.; Mahabir, V.; Ramsewak, S.; Naraynsingh, V. Microbial profile of diabetic foot infections in Trinidad and Tobago. Prim. Care Diabetes 2013, 7, 303-308. [CrossRef] [PubMed]
66. Mendes, J.J.; Marques-Costa, A.; Vilela, C.; Neves, J.; Candeias, N.; Cavaco-Silva, P.; Melo-Cristino, J. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res. Clin. Pract. 2012, 95, 153-161. [CrossRef] [PubMed]
67. Radji, M.; Putri, C.S.; Fauziyah, S. Antibiotic therapy for diabetic foot infections in a tertiary care hospital in Jakarta, Indonesia. Diabetes Metab. Syndr. 2014, 8, 221-224. [CrossRef] [PubMed]
68. El-Tahawy, A.T. Bacteriology of diabetic foot. Saudi Med. J. 2000, 21, 344-347. [PubMed]
69. Guira, O.; Tiéno, H.; Traoré, S.; Diallo, I.; Ouangré, E.; Sagna, Y.; Zabsonré, J.; Yanogo, D.; Traoré, S.S.; Drabo, Y.J. The bacterial microflora of diabetic foot infection and factors determining its spectrum in Ouagadougou (Burkina Faso). Bull. Soc. Pathol. Exot. 2015, 108, 307-311. [CrossRef] [PubMed]
70. Unachukwu, C.N.; Obunge, O.K.; Odia, O.J. The bacteriology of diabetic foot ulcers in Port Harcourt, Nigeria. Niger. J. Med. 2005, 14, 173-176. [PubMed]
71. Katz, D.E.; Friedman, N.D.; Ostrovski, E.; Ravid, D.; Amrami, N.; Avivi, D.; Mengesha, B.; Zaidenstein, R.; Lazarovitch, T.; Dadon, M.; et al. Diabetic foot infection in hospitalized adults. J. Infect. Chemother. 2016, 22, 167-173. [CrossRef] [PubMed]
72. Cervantes-Garcia, E.; García-González, R.; Reséndiz-Albor, A.; Salazar-Schettino, P.M. Infections of diabetic foot ulcers with methicillin-resistant Staphylococcus aureus. Int. J. Low. Extrem. Wounds 2015, 14, 44-49. [CrossRef] [PubMed]
73. Lelievre, H.; Lina, G.; Jones, M.E.; Olive, C.; Forey, F.; Roussel-Delvallez, M.; Nicolas-Chanoine, M.H.; Bébéar, C.M.; Jarlier, V.; Andremont, A.; et al. Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J. Clin. Microbiol. 1999, 37, 3452-3457. [PubMed]
74. Ertugrul, B.M.; Oncul, O.; Tulek, N.; Willke, A.; Sacar, S.; Tunccan, O.G.; Yilmaz, E.; Kaya, O.; Ozturk, B.; Turhan, O.; et al. A prospective, multi-center study: Factors related to the management of diabetic foot infections. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 2345-2352. [CrossRef] [PubMed]
75. Leclercq, R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin. Microbiol. Infect. 2009, 15, 224-231. [CrossRef] [PubMed]
76. Société de Pathologie Infectieuse de Langue Française. Management of diabetic foot infections. Short text. Med. Mal. Infect. 2007, 37, 1-25.
77. American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 1999, 22, 1354-1360.
78. Eleftheriadou, I.; Tentolouris, N.; Argiana, V.; Jude, E.; Boulton, A.J. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs 2010, 70, 1785-1797. [CrossRef] [PubMed]
79. Lagacé-Wiens, P.R.; Ormiston, D.; Nicolle, L.E.; Hilderman, T.; Embil, J. The diabetic foot clinic: Not a significant source for acquisition of methicillin-resistant Staphylococcus aureus. Am. J. Infect. Control 2009, 37, 587-589. [CrossRef] [PubMed]
80. Pittet, D.; Hugonnet, S.; Harbarth, S.; Mourouga, P.; Sauvan, V.; Touveneau, S.; Perneger, T.V. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000, 356, 1307-1312. [CrossRef]
81. Zenelaj, B.; Bouvet, C.; Lipsky, B.A.; Uçkay, I. Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens? Int. J. Low. Extrem. Wounds 2014, 13, 263-272. [CrossRef] [PubMed]
82. Richard, J.L.; Sotto, A.; Jourdan, N.; Combescure, C.; Vannereau, D.; Rodier, M.; Lavigne, J.P. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008, 34, 363-369. [CrossRef] [PubMed]
83. Aragón-Sánchez, J.; Lázaro-Martínez, J.L.; Quintana-Marrero, Y.; Hernández-Herrero, M.J.; García-Morales, E.; Cabrera-Galván, J.J.; Beneit-Montesinos, J.V. Are diabetic foot ulcers complicated by MRSA osteomyelitis associated with worse prognosis? Outcomes of a surgical series. Diabet. Med. 2009, 26, 552-555. [CrossRef] [PubMed]
84. Chang, S.; Sievert, D.M.; Hageman, J.C.; Boulton, M.L.; Tenover, F.C.; Downes, F.P.; Shah, S.; Rudrik, J.T.; Pupp, G.R.; Brown, W.J.; et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 2003, 348, 1342-1347. [CrossRef] [PubMed]
85. Dezfulian, A.; Aslani, M.M.; Oskoui, M.; Farrokh, P.; Azimirad, M.; Dabiri, H.; Salehian, M.T.; Zali, M.R. Identification and characterization of a high vancomycin-resistant Staphylococcus aureus harboring vanA gene cluster isolated from diabetic foot ulcer. Iran. J. Basic Med. Sci. 2012, 15, 803-806. [PubMed]
86. Foster, T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3, 948-958. [CrossRef] [PubMed]
87. Ambrosch, A.; Haefner, S.; Jude, E.; Lobmann, R. Diabetic foot infections: Microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus. Int. Wound J. 2011, 8, 567-577. [CrossRef] [PubMed]
88. Cunningham, R.; Cockayne, A.; Humphreys, H. Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infections. J. Med. Microbiol. 1996, 44, 157-164. [CrossRef] [PubMed]
89. Clarke, S.R.; Brummell, K.J.; Horsburgh, M.J.; McDowell, P.W.; Mohamad, S.A.; Stapleton, M.R.; Acevedo, J.; Read, R.C.; Day, N.P.; Peacock, S.J.; et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 2006, 193, 1098-1108. [CrossRef] [PubMed]
90. Weidenmaier, C.; Kokai-Kun, J.F.; Kristian, S.A.; Chanturiya, T.; Kalbacher, H.; Gross, M.; Nicholson, G.; Neumeister, B.; Mond, J.J.; Peschel, A. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 2004, 10, 243-245. [CrossRef] [PubMed]
91. Burian, M.; Rautenberg, M.; Kohler, T.; Fritz, M.; Krismer, B.; Unger, C.; Hoffmann, W.H.; Peschel, A.; Wolz, C.; Goerke, C. Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J. Infect. Dis. 2010, 201, 1414-1421. [CrossRef] [PubMed]
92. Cho, S.H.; Strickland, I.; Boguniewicz, M.; Leung, D.Y. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J. Allergy Clin. Immunol. 2001, 108, 269-274. [CrossRef] [PubMed]
93. Shi, S.; Zhang, X. Interaction of Staphylococcus aureus with osteoblasts. Exp. Ther. Med. 2012, 3, 367-370. [PubMed]
94. Proctor, R.A.; von Eiff, C.; Kahl, B.C.; Becker, K.; McNamara, P.; Herrmann, M.; Peters, G. Small colony variants: A pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 2006, 4, 295-305. [CrossRef] [PubMed]
95. Tuchscherr, L.; Heitmann, V.; Hussain, M.; Viemann, D.; Roth, J.; von Eiff, C.; Peters, G.; Becker, K.; Löffler, B. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J. Infect. Dis. 2010, 202, 1031-1040. [CrossRef] [PubMed]
96. Von Eiff, C.; Becker, K.; Metze, D.; Lubritz, G.; Hockmann, J.; Schwarz, T.; Peters, G. Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: A cause for antibiotic treatment failure in a patient with darier's disease. Clin. Infect. Dis. 2001, 32, 1643-1647. [CrossRef] [PubMed]
97. Baumert, N.; von Eiff, C.; Schaaff, F.; Peters, G.; Proctor, R.A.; Sahl, H.G. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb. Drug Res. 2002, 8, 253-260. [CrossRef] [PubMed]
98. Garcia, L.G.; Lemaire, S.; Kahl, B.C.; Becker, K.; Proctor, R.A.; Denis, O.; Tulkens, P.M.; Van Bambeke, F. Antibiotic activity against small-colony variants of Staphylococcus aureus: Review of in vitro, animal and clinical data. J. Antimicrob. Chemother. 2013, 68, 1455-1464. [CrossRef] [PubMed]
99. Proctor, R.A.; Peters, G. Small colony variants in staphylococcal infections: Diagnostic and therapeutic implications. Clin. Infect. Dis. 1998, 27, 419-422. [CrossRef] [PubMed]
100. Podbielska, A.; Galbowska, H.; Stelmach, E.; Mlynarczyk, G.; Olszewski, W.L. Slime production by Staphylococcus aureus and Staphylococcus epidermidis strains isolated from patients with diabetic foot ulcers. Arch. Immunol. Ther. Exp. 2010, 58, 321-324. [CrossRef] [PubMed]
101. Bergamini, T.M.; Corpus, R.A.; Hoeg, K.L.; Brittian, K.R.; Peyton, J.C.; Cheadle, W.G. Immune regulation of bacterial biofilm graft infection. ASAIO J. 1994, 40, 219-226. [CrossRef] [PubMed]
102. Steinberg, D.; Poran, S.; Shapira, L. The effect of extracellular polysaccharides from Streptococcus mutans on the bactericidal activity of human neutrophils. Arch. Oral Biol. 1999, 44, 437-444. [CrossRef]
103. Yasuda, H.; Ajiki, Y.; Aoyama, J.; Yokota, T. Interaction between human polymorphonuclear leucocytes and bacteria released from in vitro bacterial biofilm models. J. Med. Microbiol. 1994, 41, 359-367. [CrossRef] [PubMed]
104. Bjarnsholt, T.; Kirketerp-Moller, K.; Jensen, P.O.; Madsen, K.G.; Philipps, R.; Krogfelt, K.; Hoiby, N.; Givskov, M. Why chronic wounds will not heal: A novel hypothesis. Wound Repair. Regen. 2008, 16, 2-10. [CrossRef] [PubMed]
105. Vandenesch, F.; Lina, G.; Henry, T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: A redundant arsenal of membrane-damaging virulence factors? Front. Cell. Infect. Microbiol. 2012, 2, 12. [CrossRef] [PubMed]
106. Grumann, D.; Nubel, U.; Broker, B.M. Staphylococcus aureus toxins-Their functions and genetics. Infect. Genet. Evol. 2014, 21, 583-592. [CrossRef] [PubMed]
107. Otto, M. Staphylococcus aureus toxins. Curr. Opin. Microbiol. 2014, 17, 32-37. [CrossRef] [PubMed]
108. Xiong, Y.Q.; Willard, J.; Yeaman, M.R.; Cheung, A.L.; Bayer, A.S. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J. Infect. Dis. 2006, 194, 1267-1275. [CrossRef] [PubMed]
109. Valeva, A.;Walev, I.; Pinkernell, M.;Walker, B.; Bayley, H.; Palmer, M.; Bhakdi, S. Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc. Natl. Acad. Sci. USA 1997, 94, 11607-11611. [CrossRef] [PubMed]
110. Sotto, A.; Richard, J.L.; Messad, N.; Molinari, N.; Jourdan, N.; Schuldiner, S.; Sultan, A.; Carrière, C.; Canivet, B.; Landraud, L.; et al. Distinguishing colonization from infection with Staphylococcus aureus in diabetic foot ulcers with miniaturized oligonucleotide arrays: A French multicenter study. Diabetes Care 2012, 35, 617-623. [CrossRef] [PubMed]
111. Wang, R.; Braughton, K.R.; Kretschmer, D.; Bach, T.H.; Queck, S.Y.; Li, M.; Kennedy, A.D.; Dorward, D.W.; Klebanoff, S.J.; Peschel, A.; et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007, 13, 1510-1514. [CrossRef] [PubMed]
112. Li, M.; Diep, B.A.; Villaruz, A.E.; Braughton, K.R.; Jiang, X.; DeLeo, F.R.; Chambers, H.F.; Lu, Y.; Otto, M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2009, 106, 5883-5888. [CrossRef] [PubMed]
113. Chatterjee, S.S.; Joo, H.S.; Duong, A.C.; Dieringer, T.D.; Tan, V.Y.; Song, Y.; Fischer, E.R.; Cheung, G.Y.; Li, M.; Otto, M. Essential Staphylococcus aureus toxin export system. Nat. Med. 2013, 19, 364-367. [CrossRef] [PubMed]
114. Surewaard, B.G.; de Haas, C.J.; Vervoort, F.; Rigby, K.M.; DeLeo, F.R.; Otto, M.; van Strijp, J.A.; Nijland, R. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cell. Microbiol. 2013, 15, 1427-1437. [CrossRef] [PubMed]
115. Dumont, A.L.; Nygaard, T.K.; Watkins, R.L.; Smith, A.; Kozhaya, L.; Kreiswirth, B.N.; Shopsin, B.; Unutmaz, D.; Voyich, J.M.; Torres, V.J. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol. Microbiol. 2011, 79, 814-825. [CrossRef] [PubMed]
116. Ventura, C.L.; Malachowa, N.; Hammer, C.H.; Nardone, G.A.; Robinson, M.A.; Kobayashi, S.D.; DeLeo, F.R. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS ONE 2010, 5, e11634. [CrossRef] [PubMed]
117. Panton, P.N.; Valentine, F.C.O. Staphylococcal toxin. Lancet 1932, 219, 506-508. [CrossRef]
118. Gravet, A.; Colin, D.A.; Keller, D.; Girardot, R.; Monteil, H.; Prevost, G. Characterization of a novel structural member, LukE-LukD, of the bi-component staphylococcal leucotoxins family. FEBS Lett. 1998, 436, 202-208. [CrossRef]
119. Morinaga, N.; Kaihou, Y.; Noda, M. Purification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol. Immunol. 2003, 47, 81-90. [CrossRef] [PubMed]
120. Nilsson, I.M.; Hartford, O.; Foster, T.; Tarkowski, A. Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Inf. Immun. 1999, 67, 1045-1049.
121. Malachowa, N.; Whitney, A.R.; Kobayashi, S.D.; Sturdevant, D.E.; Kennedy, A.D.; Braughton, K.R.; Shabb, D.W.; Diep, B.A.; Chambers, H.F.; Otto, M.; et al. Global changes in Staphylococcus aureus gene expression in human blood. PLoS ONE 2011, 6, e18617. [CrossRef] [PubMed]
122. Sotto, A.; Lina, G.; Richard, J.L.; Combescure, C.; Bourg, G.; Vidal, L.; Jourdan, N.; Etienne, J.; Lavigne, J.P. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers. Diabetes Care 2008, 31, 2318-2324. [CrossRef] [PubMed]
123. Boyle-Vavra, S.; Daum, R.S. Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin. Lab. Investig. 2007, 87, 3-9. [CrossRef] [PubMed]
124. Kaneko, J.; Kimura, T.; Kawakami, Y.; Tomita, T.; Kamio, Y. Panton-valentine leukocidin genes in a phage-like particle isolated from mitomycin C-treated Staphylococcus aureus V8 (ATCC 49775). Biosci. Biotechnol. Biochem. 1997, 61, 1960-1962. [CrossRef] [PubMed]
125. Narita, S.; Kaneko, J.; Chiba, J.; Piemont, Y.; Jarraud, S.; Etienne, J.; Kamio, Y. Phage conversion of Panton-Valentine leukocidin in Staphylococcus aureus: Molecular analysis of a PVL-converting phage, phiSLT. Gene 2001, 268, 195-206. [CrossRef]
126. Dupieux, C.; Blondé, R.; Bouchiat, C.; Meugnier, H.; Bes, M.; Laurent, S.; Vandenesch, F.; Laurent, F.; Tristan, A. Community-acquired infections due to Staphylococcus argenteus lineage isolates harbouring the Panton-Valentine leucocidin, France, 2014. Euro Surveill. 2015, 20, 21154. [CrossRef] [PubMed]
127. Shallcross, L.J.; Fragaszy, E.; Johnson, A.M.; Hayward, A.C. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: A systematic review and meta-analysis. Lancet Infect. Dis. 2013, 13, 43-54. [CrossRef]
128. Gillet, Y.; Issartel, B.; Vanhems, P.; Fournet, J.C.; Lina, G.; Bes, M.; Vandenesch, F.; Piemont, Y.; Brousse, N.; Floret, D.; et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359, 753-759. [CrossRef]
129. Vandenesch, F.; Naimi, T.; Enright, M.C.; Lina, G.; Nimmo, G.R.; Heffernan, H.; Liassine, N.; Bes, M.; Greenland, T.; Reverdy, M.E.; et al. Community- acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg. Infect. Dis. 2003, 9, 978-984. [CrossRef] [PubMed]
130. Shukla, S.K.; Karow, M.E.; Brady, J.M.; Stemper, M.E.; Kislow, J.; Moore, N.;Wroblewski, K.; Chyou, P.H.; Warshauer, D.M.; Reed, K.D.; et al. Virulence genes and genotypic associations in nasal carriage, community-associated methicillin- susceptible and methicillin-resistant USA400 Staphylococcus aureus isolates. J. Clin. Microbiol. 2010, 48, 3582-3592. [CrossRef] [PubMed]
131. Kiliç, A.; Doğan, E.; Kaya, S.; Baysallar, M. Investigation of the presence of mecC and Panton-Valentine leukocidin genes in Staphylococcus aureus strains isolated from clinical specimens during seven years period. Mikrobiyol. Bulteni 2015, 49, 594-599. [CrossRef]
132. Santosaningsih, D.; Santoso, S.; Budayanti, N.S.; Suata, K.; Lestari, E.S.; Wahjono, H.; Djamal, A.; Kuntaman, K.; van Belkum, A.; Laurens, M.; et al. Characterisation of clinical Staphylococcus aureus isolates harbouring mecA or Panton-Valentine leukocidin genes from four tertiary care hospitals in Indonesia. Trop. Med. Int. Health 2016, 21, 610-618. [CrossRef] [PubMed]
133. Motamedi, H.; Rahmat Abadi, S.S.; Moosavian, S.M.; Torabi, M. The association of Panton-Valentine leukocidin and mecA genes in Methicillin-Resistant Staphylococcus aureus isolates from patients referred to Educational Hospitals in Ahvaz, Iran. Jundishapur J. Microbiol. 2015, 8, e22021. [CrossRef] [PubMed]
134. Yu, F.; Liu, Y.; Lv, J.; Qi, X.; Lu, C.; Ding, Y.; Li, D.; Liu, H.;Wang, L. Antimicrobial susceptibility, virulence determinant carriage and molecular characteristics of Staphylococcus aureus isolates associated with skin and soft tissue infections. Braz. J. Infect. Dis. 2015, 19, 614-622. [CrossRef] [PubMed]
135. Conceição, T.; Coelho, C.; de Lencastre, H.; Aires-de-Sousa, M. Frequent occurrence of oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) strains in two African countries. J. Antimicrob. Chemother. 2015, 70, 3200-3204. [PubMed]
136. Chen, B.; Dai, X.; He, B.; Pan, K.; Li, H.; Liu, X.; Bao, Y.; Lao, W.; Wu, X.; Yao, Y.; Huang, S. Differences in Staphylococcus aureus nasal carriage and molecular characteristics among community residents and healthcare workers at Sun Yat-Sen University, Guangzhou, Southern China. BMC Infect. Dis. 2015, 15, 303. [CrossRef] [PubMed]
137. Morgan, M.S. Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia. Int. J. Antimicrob. Agents 2007, 30, 289-296. [CrossRef] [PubMed]
138. Rossney, A.S.; Shore, A.C.; Morgan, P.M.; Fitzgibbon, M.M.; O'Connell, B.; Coleman, D.C. The emergence and importation of diverse genotypes of methicillin-resistant Staphylococcus aureus (MRSA) harboring the Panton-Valentine leukocidin gene (pvl) reveal that pvl is a poor marker for community-acquired MRSA strains in Ireland. J. Clin. Microbiol. 2007, 45, 2554-2563. [CrossRef] [PubMed]
139. Abdulgader, S.M.; Shittu, A.O.; Nicol, M.P.; Kaba, M. Molecular epidemiology of Methicillin-resistant Staphylococcus aureus in Africa: A systematic review. Front. Microbiol. 2015, 6, 348. [CrossRef] [PubMed]
140. Bazzi, A.M.; Rabaan, A.A.; Fawarah, M.M.; Al-Tawfiq, J.A. Prevalence of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in a Saudi Arabian hospital. J. Infect. Public Health 2015, 8, 364-368. [CrossRef] [PubMed]
141. Ohadian Moghadam, S.; Pourmand, M.R.; Mahmoudin, M.; Sadighian, H. Molecular characterization of methicillin-resistant Staphylococcus aureus: Characterization of major clones and emergence of epidemic clones of sequence type (ST) 36 and ST 121 in Tehran, Iran. FEMS Microbiol. Lett. 2015, 362, fnv043. [CrossRef] [PubMed]
142. Liu, X.; Liang, J.; Jiang, Y.;Wang, B.; Yuan, H.; Zhang, L.; Zhou, Y.; Xu, H.; Zhou,W. Molecular characteristics of community-acquired methicillin-resistant Staphylococcus aureus strains isolated from outpatients with skin and soft tissue infections in Wuhan, China. Pathog. Dis. 2016, 74, ftw026. [CrossRef] [PubMed]
143. David, M.Z.; Acree, M.E.; Sieth, J.J.; Boxrud, D.J.; Dobbins, G.; Lynfield, R.; Boyle-Vavra, S.; Daum, R.S. Pediatric Staphylococcus aureus isolate genotypes and infections from the dawn of the Community-Associated Methicillin-Resistant S. aureus epidemic era in Chicago, 1994 to 1997. J. Clin. Microbiol. 2015, 53, 2486-2491. [CrossRef] [PubMed]
144. Post, V.; Wahl, P.; Uçkay, I.; Ochsner, P.; Zimmerli, W.; Corvec, S.; Loiez, C.; Richards, R.G.; Moriarty, F. Phenotypic and genotypic characterisation of Staphylococcus aureus causing musculoskeletal infections. Int. J. Med. Microbiol. 2014, 304, 565-576. [CrossRef] [PubMed]
145. Dunyach-Remy, C.; Courtais-Coulon, C.; DeMattei, C.; Jourdan, N.; Schuldiner, S.; Sultan, A.; Carrière, C.; Alonso, S.; Sotto, A.; Lavigne, J.P. Link between nasal carriage of Staphylococcus aureus and infected diabetic foot ulcers. Unpublished work, 2016.
146. Stappers, M.H.T.; Hagen, F.; Reimnitz, P.; Mouton, J.W.; Meis, J.F.; Gyssens, I.C. Direct molecular versus culture-based assessment of Gram-positive cocci in biopsies of patients with major abscesses and diabetic foot infections. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 1885-1892. [CrossRef] [PubMed]
147. Tristan, A.; Bes, M.; Meugnier, H.; Lina, G.; Bozdogan, B.; Courvalin, P.; Reverdy, M.E.; Enright, M.C.; Vandenesch, F.; Etienne, J. Global distribution of Panton-Valentine leukocidine positive methicillin-resistant Staphylococcus aureus, 2006. Emerg. Infect. Dis. 2007, 13, 594-600. [CrossRef] [PubMed]
148. Antri, K.; Rouzic, N.; Dauwalder, O.; Boubekri, I.; Bes, M.; Lina, G.; Vandenesch, F.; Tazir, M.; Ramdani-Bouguessa, N.; Etienne, J. High prevalence of methicillin-resistant Staphylococcus aureus clone ST80-IV in hospital and community settings in Algiers. Clin. Microbiol. Infect. 2011, 17, 526-532. [CrossRef] [PubMed]
149. Ben Nejma, M.; Mastouri, M.; Bel Hadj Jrad, B.; Nour, M. Characterization of ST80 Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus clone in Tunisia. Diagn. Microbiol. Infect. Dis. 2008, 77, 20-24. [CrossRef] [PubMed]
150. Lamy, B.; Laurent, F.; Gallon, O.; Doucet-Populaire, F.; Etienne, J.; Decousser, J.W. Antibacterial resistance, genes encoding toxins and genetic background among Staphylococcus aureus isolated from community-acquired skin and soft tissue infections in France: A national prospective survey. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1279-1284. [CrossRef] [PubMed]
151. Durupt, F.; Mayor, L.; Bes, M.; Reverdy, M.E.; Vandenesch, F.; Thomas, L.; Etienne, J. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br. J. Dermatol. 2007, 157, 1161-1167. [CrossRef] [PubMed]
152. Issartel, B.; Tristan, A.; Lechevallier, S.; Bruyère, F.; Lina, G.; Garin, B.; Lacassin, F.; Bes, M.; Vandenesch, F.; Etienne, J. Frequent carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates from surgically drained abscesses. J. Clin. Microbiol. 2005, 43, 3203-3207. [CrossRef] [PubMed]
153. Puzniak, L.A.; Quintana, A.; Wible, M.; Babinchak, T.; McGovern, P.C. Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials. Diagn. Microbiol. Infect. Dis. 2014, 79, 261-265.
154. Senneville, E.; Brière, M.; Neut, C.; Messad, N.; Lina, G.; Richard, J.L.; Sotto, A.; Lavigne, J.P.; French Study Group on the Diabetic Foot. First report of the predominance of clonal complex 398 Staphylococcus aureus strains in osteomyelitis complicating diabetic foot ulcers: A national French study. Clin. Microbiol. Infect. 2014, 20, O274-O277. [CrossRef] [PubMed]
155. Alonzo, F., 3rd; Benson, M.A.; Chen, J.; Novick, R.P.; Shopsin, B.; Torres, V.J. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol. Microbiol. 2012, 83, 423-435. [CrossRef] [PubMed]
156. Feng, S.H.; Chu, Y.J.; Wang, P.H.; Jun, X.; Min, D.; Li, X.M. Risk factors and gene type for infections of MRSA in diabetic foot patients in Tianjin, China. Int. J. Low. Extrem. Wounds 2013, 12, 106-112. [CrossRef] [PubMed]
157. Nhan, T.X.; Leclercq, R.; Cattoir, V. Prevalence of toxin genes in consecutive clinical isolates of Staphylococcus aureus and clinical impact. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30, 719-725. [CrossRef] [PubMed]
158. Becker, K.; Friedrich, A.W.; Lubritz, G.; Weilert, M.; Peters, G.; von Eiff, C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J. Clin. Microbiol. 2003, 41, 1434-1439. [CrossRef] [PubMed]
159. Sila, J.; Sauer, P.; Kolar, M. Comparison of the prevalence of genes coding for enterotoxins, exfoliatins, Panton-Valentine leukocidin and Tsst-1 between methicillin-resistant and methicillin-susceptible isolates of Staphylococcus aureus at the University Hospital in Olomouc. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2009, 153, 215-218. [CrossRef] [PubMed]
160. Spaulding, A.R.; Salgado-Pabon,W.; Kohler, P.L.; Horswill, A.R.; Leung, D.Y.; Schlievert, P.M. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 2013, 26, 422-447. [CrossRef] [PubMed]
161. Vu, B.G.; Stach, C.S.; Salgado-Pabon, W.; Diekema, D.J.; Gardner, S.E.; Schlievert, P.M. Superantigens of Staphylococcus aureus from patients with diabetic foot ulcers. J. Infect. Dis. 2014, 210, 1920-1927. [CrossRef] [PubMed]
162. Lina, G.; Bohach, G.A.; Nair, S.P.; Hiramatsu, K.; Jouvin-Marche, E.; Mariuzza, R. Standard nomenclature for the superantigens expressed by Staphylococcus. J. Infect. Dis. 2004, 189, 2334-2336. [CrossRef] [PubMed]
163. Diegelmann, R.F.; Evans, M.C. Wound healing: An overview of acute, fibrotic and delayed healing. Front. Biosci. 2004, 9, 283-289. [CrossRef] [PubMed]
164. Dinges, M.M.; Orwin, P.M.; Schlievert, P.M. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 2000, 13, 16-34. [CrossRef] [PubMed]
165. Lee, H.W.; Kim, S.M.; Kim, J.M.; Oh, B.M.; Kim, J.Y.; Jung, H.J.; Lim, H.J.; Kim, B.S.; Lee, W.J.; Lee, S.J.; et al. Potential immunoinflammatory role of staphylococcal enterotoxin A in atopic dermatitis: Immunohistopathological analysis and in vitro assay. Ann. Dermatol. 2013, 25, 173-180. [CrossRef] [PubMed]
166. Wilson, G.J.; Seo, K.S.; Cartwright, R.A.; Connelley, T.; Chuang-Smith, O.N.; Merriman, J.A.; Guinane, C.M.; Park, J.Y.; Bohach, G.A.; Schlievert, P.M.; et al. A novel core genome-encoded superantigen contributes to lethality of community-associated MRSA necrotizing pneumonia. PLoS Pathog. 2011, 7, e1002271. [CrossRef] [PubMed]
167. Boquet, P.; Lemichez, E. Bacterial virulence factors targeting Rho GTPases: Parasitism or symbiosis? Trends Cell Biol. 2003, 13, 238-246. [CrossRef]
168. Boyer, L.; Doye, A.; Rolando, M.; Flatau, G.; Munro, P.; Gounon, P.; Clément, R.; Pulcini, C.; Popoff, M.R.; Mettouchi, A.; et al. Induction of transient macroapertures in endothelial cells through RhoA inhibition by Staphylococcus aureus factors. J. Cell Biol. 2006, 173, 809-819. [CrossRef] [PubMed]
169. Lemichez, E.; Lecuit, M.; Nassif, X.; Bourdoulous, S. Breaking the wall: Targeting of the endothelium by pathogenic bacteria. Nat. Rev. Microbiol. 2010, 8, 93-104. [CrossRef] [PubMed]
170. Rolando, M.; Munro, P.; Stefani, C.; Auberger, P.; Flatau, G.; Lemichez, E. Injection of Staphylococcus aureus EDIN by the Bacillus anthracis protective antigen machinery induces vascular permeability. Infect. Immun. 2009, 77, 3596-3601. [CrossRef] [PubMed]
171. Munro, P.; Benchetrit, M.; Nahori, M.A.; Stefani, C.; Clément, R.; Michiels, J.F.; Landraud, L.; Dussurget, O.; Lemichez, E. The Staphylococcus aureus epidermal cell differentiation inhibitor toxin promotes formation of infection foci in a mouse model of bacteremia. Infect. Immun. 2010, 78, 3404-3411. [CrossRef] [PubMed]
172. Inoue, S.; Sugai, M.; Murooka, Y.; Paik, S.Y.; Hong, Y.M.; Ohgai, H.; Suginaka, H. Molecular cloning and sequencing of the epidermal cell differentiation inhibitor gene from Staphylococcus aureus. Biochem. Biophys. Res. Commun. 1991, 174, 459-464. [CrossRef]
173. Wilde, C.; Aktories, K. The Rho-ADP-ribosylating C3 exoenzyme from Clostridium botulinum and related C3-like transferases. Toxicon 2001, 39, 1647-1660. [CrossRef]
174. Franke, G.C.; Böckenholt, A.; Sugai, M.; Rohde, H.; Aepfelbacher, M. Epidemiology, variable genetic organization and regulation of the EDIN-B toxin in Staphylococcus aureus from bacteraemic patients. Microbiology 2010, 156, 860-872. [CrossRef] [PubMed]
175. Yamaguchi, T.; Hayashi, T.; Takami, H.; Ohnishi, M.; Murata, T.; Nakayama, K.; Asakawa, K.; Ohara, M.; Komatsuzawa, H.; Sugai, M. Complete nucleotide sequence of a Staphylococcus aureus exfoliative toxin B plasmid and identification of a novel ADP-ribosyltransferase, EDIN-C. Infect. Immun. 2001, 69, 7760-7771. [CrossRef] [PubMed]
176. Czech, A.; Yamaguchi, T.; Bader, L.; Linder, S.; Kaminski, K.; Sugai, M.; Aepfelbacher, M. Prevalence of Rho-inactivating epidermal cell differentiation inhibitor toxins in clinical Staphylococcus aureus isolates. J. Infect. Dis. 2001, 184, 785-788. [CrossRef] [PubMed]
177. Munro, P.; Clément, R.; Lavigne, J.P.; Pulcini, C.; Lemichez, E.; Landraud, L. High prevalence of edin-C encoding RhoA-targeting toxin in clinical isolates of Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30, 965-972. [CrossRef] [PubMed]